FDA cites companies for CGMP violations, telehealth firms for illegally marketing GLP-1 drugs - RAPS
FDA has cited companies for CGMP violations and telehealth firms for illegally marketing GLP-1 drugs, indicating increased enforcement against non-compliant manufacturing and unauthorized marketing.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities, and telehealth firms marketing GLP-1 drugs. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate; ongoing compliance monitoring expected.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA is actively citing companies for CGMP violations and targeting telehealth firms for illegal marketing of GLP-1 drugs, signaling a stricter enforcement posture.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities, and telehealth firms marketing GLP-1 drugs.
What you must do
Review and ensure all manufacturing processes comply with CGMP regulations; for telehealth firms, cease any unauthorized marketing of GLP-1 drugs and verify compliance with FDA marketing requirements.
Deadline
Immediate; ongoing compliance monitoring expected.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)